New Cholesterol Treatment Guidelines Hard to Swallow for Non-Statin Manufacturers in Cardiovascular Drug Market
Updated guidelines for the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) could well give the statin market a substantial boost over the coming years, but they will pose a significant challenge to developers of other drug classes in the cardiovascular marketplace, according to analysts with research and consulting firm GlobalData.
The new guidelines, released by a task force from the American College of Cardiology (ACC) and the American Heart Association (AHA), promote the use of statins alone for the reduction of low-density lipoprotein cholesterol (LDL-C), or 'bad cholesterol'.
Eric J. Dimise, PhD, and Rebecca C. Wong, MSc, GlobalData's Analysts covering Cardiovascular & Metabolic Disorders, say that these guidelines will prove particularly “hard to swallow” for manufacturers of other lipid-lowering drug classes, such as Zetia (ezetimibe/Merck) and Trilipix (fenofibric acid/AbbVie), as the new recommendations all but discredit the usefulness of these products.
Conversely, the analysts believe that the support received from statin suppliers is not at all surprising. AstraZeneca, for instance, is leveraging the new guidelines to promote Crestor (rosuvastatin), which will remain under patent protection into 2016.
Rebecca C. Wong says: “Now that statins are officially recommended as the go-to therapy, drugs such as Lipitor (atorvastatin), Crestor and Zocor (simvastatin) are likely to retain market dominance for the treatment of ASCVD. Meanwhile, drugs in alternative therapeutic classes could well experience greater difficulty in gaining physician uptake and patient shares.”
Instead of employing a 'treat-to-target' approach to cholesterol reduction, the new guidelines promote a more opaque goal of 'treat to reduce risk', with an increased emphasis on healthy lifestyles.
However, prescribing physicians are far from achieving a consensus regarding these directions. Eric J. Dimise believes that physicians will not necessarily break from what they perceive to be the tried-and-true, treat-to-target approach.
As such, Dimise concludes: “It is risky to say that the statin market will double in size between November 2013 and the patent expiry of Crestor in 2016 as a result of these guidelines. However, suggesting that it will experience a boost is a reasonable and well-founded proposition that GlobalData can support.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance